{
    "hands_on_practices": [
        {
            "introduction": "Distinguishing between a hypertrophic scar and a keloid is a critical first step in management, and while often based on clinical appearance, the definitive differences lie at the microscopic level. This practice challenges you to apply your knowledge of wound healing pathobiology to interpret a set of classic histopathological findings. By analyzing collagen architecture and cellular markers, you will solidify your understanding of why these two forms of abnormal scarring behave so differently .",
            "id": "4449843",
            "problem": "A dermal biopsy from a firm, slowly enlarging scar shows extracellular matrix changes and cellular markers measured by routine histopathology and immunohistochemistry. The collagen type $\\mathrm{I}$ to type $\\mathrm{III}$ ratio is $4:1$. The collagen is organized in thick, glassy, eosinophilic bundles with hyalinization and disorganized, whorled architecture, and immunostaining for alpha-smooth muscle actin ($\\alpha$-SMA) reveals sparse positivity in stromal cells. Using fundamental principles of cutaneous wound healing and scar formation—namely, that granulation tissue increases collagen type $\\mathrm{III}$ early and remodeling shifts the matrix toward collagen type $\\mathrm{I}$, and that myofibroblasts (marked by $\\alpha$-SMA) mediate contractility and parallel fiber alignment under mechanical tension—determine whether these findings are more consistent with a keloid or a hypertrophic scar and select the option that most accurately explains why.\n\nOptions:\nA. Keloid; predominance of collagen type $\\mathrm{I}$ with a collagen type $\\mathrm{I}$ to type $\\mathrm{III}$ ratio of $4:1$, hyalinized thick glassy bundles with disorganized “keloidal collagen,” and sparse $\\alpha$-SMA staining indicate low myofibroblast content and excessive, disorganized collagen deposition typical of keloids.\n\nB. Hypertrophic scar; a collagen type $\\mathrm{I}$ to type $\\mathrm{III}$ ratio of $4:1$ together with sparse $\\alpha$-SMA supports a tension-driven, contractile scar that is confined to the original wound.\n\nC. Keloid; parallel collagen fibers with nodular architecture, numerous thick-walled vessels, and strong $\\alpha$-SMA positivity are hallmark features of keloids.\n\nD. Hypertrophic scar; lower collagen type $\\mathrm{I}$ to type $\\mathrm{III}$ ratios and strong $\\alpha$-SMA positivity define hypertrophic scars, matching the biopsy findings reported.\n\nE. Indeterminate; the collagen ratio and $\\alpha$-SMA staining overlap sufficiently between entities that histology cannot distinguish keloid from hypertrophic scar in this case.",
            "solution": "The problem statement is evaluated to be valid as it is scientifically grounded, self-contained, well-posed, objective, and presents a solvable problem based on established principles of dermatopathology.\n\nThe problem requires a differential diagnosis between a keloid and a hypertrophic scar based on a specific set of histopathological findings. The provided findings are:\n1.  A collagen type $\\mathrm{I}$ to type $\\mathrm{III}$ ratio of $4:1$.\n2.  Collagen morphology described as \"thick, glassy, eosinophilic bundles with hyalinization.\"\n3.  Collagen architecture described as \"disorganized, whorled.\"\n4.  Immunohistochemistry showing \"sparse positivity for alpha-smooth muscle actin ($\\alpha$-SMA) in stromal cells.\"\n\nThe provided fundamental principles for interpretation are:\n1.  Granulation tissue is rich in collagen type $\\mathrm{III}$.\n2.  The remodeling phase replaces type $\\mathrm{III}$ with type $\\mathrm{I}$ collagen.\n3.  Myofibroblasts, marked by $\\alpha$-SMA, are responsible for contractility and organizing collagen fibers into parallel arrays under mechanical tension.\n\nLet us analyze the findings in the context of these principles and the known pathology of keloids and hypertrophic scars.\n\n**Collagen Ratio and Type:**\nNormal dermis has a high ratio of type $\\mathrm{I}$ to type $\\mathrm{III}$ collagen, typically greater than $5:1$. During the initial proliferative phase of wound healing, there is an abundance of type $\\mathrm{III}$ collagen, leading to a low type $\\mathrm{I}$ to type $\\mathrm{III}$ ratio. As the scar matures and remodels, this ratio increases as type $\\mathrm{III}$ collagen is replaced by the stronger, more stable type $\\mathrm{I}$ collagen. A ratio of $4:1$ indicates a predominance of type $\\mathrm{I}$ collagen, which is expected in a mature or maturing scar. While some sources suggest keloids have a lower type $\\mathrm{I}:\\mathrm{III}$ ratio compared to hypertrophic scars, this finding is not consistent across all studies and can overlap. A ratio of $4:1$ on its own is not definitively diagnostic but is consistent with a fibroproliferative scar.\n\n**Collagen Morphology and Architecture:**\nThe description of \"thick, glassy, eosinophilic bundles with hyalinization\" and a \"disorganized, whorled architecture\" is the pathognomonic histological feature of a keloid. These large, haphazardly arranged collagen bundles are often referred to as \"keloidal collagen.\" In contrast, hypertrophic scars typically contain finer collagen bundles that are more organized, often arranged in nodules and oriented parallel to the epidermal surface. This parallel orientation is a result of the alignment of collagen fibers along lines of mechanical tension, a process mediated by myofibroblasts. The disorganized, whorled pattern described in the problem is a strong indicator of a keloid.\n\n**$\\alpha$-SMA Staining and Myofibroblasts:**\nThe problem states that immunostaining for $\\alpha$-SMA reveals \"sparse positivity.\" $\\alpha$-SMA is the characteristic marker for myofibroblasts. According to the provided principles, myofibroblasts are key cells in wound contraction and the organization of collagen under mechanical tension. Hypertrophic scars are strongly associated with mechanical tension, are often contractile, and histologically are characterized by a high number of myofibroblasts. Therefore, a hypertrophic scar would be expected to show abundant, strong staining for $\\alpha$-SMA. Conversely, keloids are thought to be less dependent on mechanical tension for their growth (they characteristically grow beyond the original wound boundaries) and are known to have a significantly lower density of myofibroblasts compared to hypertrophic scars, particularly in the central, established regions of the lesion. \"Sparse positivity\" for $\\alpha$-SMA is therefore highly consistent with a diagnosis of keloid and argues against a diagnosis of hypertrophic scar.\n\n**Synthesis of Findings:**\nThe combination of thick, hyalinized, disorganized collagen bundles (keloidal collagen) and a low myofibroblast population (sparse $\\alpha$-SMA) provides compelling evidence for a diagnosis of a keloid. The collagen ratio of $4:1$ is not inconsistent with this diagnosis.\n\nNow, we evaluate each option:\n\n**A. Keloid; predominance of collagen type $\\mathrm{I}$ with a collagen type $\\mathrm{I}$ to type $\\mathrm{III}$ ratio of $4:1$, hyalinized thick glassy bundles with disorganized “keloidal collagen,” and sparse $\\alpha$-SMA staining indicate low myofibroblast content and excessive, disorganized collagen deposition typical of keloids.**\nThis option correctly identifies the scar as a keloid. The reasoning provided is entirely consistent with our analysis. It correctly notes the predominance of type $\\mathrm{I}$ collagen at the given ratio, correctly identifies the pathognomonic \"keloidal collagen\" description, and correctly links sparse $\\alpha$-SMA staining to low myofibroblast content, all of which are characteristic features of keloids. The logic is sound and directly uses the information provided in the problem statement.\n**Verdict: Correct**\n\n**B. Hypertrophic scar; a collagen type $\\mathrm{I}$ to type $\\mathrm{III}$ ratio of $4:1$ together with sparse $\\alpha$-SMA supports a tension-driven, contractile scar that is confined to the original wound.**\nThis option incorrectly identifies the scar as a hypertrophic scar. The reasoning is flawed because it states that sparse $\\alpha$-SMA supports a \"tension-driven, contractile scar.\" As per the given principles, a contractile scar driven by tension would have abundant myofibroblasts and thus strong, not sparse, $\\alpha$-SMA staining. This statement is a direct contradiction.\n**Verdict: Incorrect**\n\n**C. Keloid; parallel collagen fibers with nodular architecture, numerous thick-walled vessels, and strong $\\alpha$-SMA positivity are hallmark features of keloids.**\nThis option correctly identifies the scar as a keloid but provides an incorrect justification. It describes \"parallel collagen fibers\" and \"strong $\\alpha$-SMA positivity.\" The problem biopsy showed \"disorganized, whorled\" fibers and \"sparse\" $\\alpha$-SMA positivity. The features listed in this option are either contrary to the findings (parallel fibers vs. disorganized; strong $\\alpha$-SMA vs. sparse) or more characteristic of a hypertrophic scar.\n**Verdict: Incorrect**\n\n**D. Hypertrophic scar; lower collagen type $\\mathrm{I}$ to type $\\mathrm{III}$ ratios and strong $\\alpha$-SMA positivity define hypertrophic scars, matching the biopsy findings reported.**\nThis option incorrectly identifies the scar as a hypertrophic scar. While strong $\\alpha$-SMA positivity is a feature of hypertrophic scars, the option falsely claims this \"match[es] the biopsy findings reported.\" The biopsy showed sparse $\\alpha$-SMA positivity. The reasoning is based on a misrepresentation of the data provided.\n**Verdict: Incorrect**\n\n**E. Indeterminate; the collagen ratio and $\\alpha$-SMA staining overlap sufficiently between entities that histology cannot distinguish keloid from hypertrophic scar in this case.**\nThis option is incorrect because the combination of findings presented is highly characteristic, allowing for a definitive diagnosis. The presence of classic \"keloidal collagen\" (thick, hyalinized, disorganized bundles) in conjunction with sparse $\\alpha$-SMA staining is a powerful combination of features pointing specifically to a keloid, not a hypertrophic scar. While some individual features might show overlap in atypical cases, the constellation of findings described here is not indeterminate.\n**Verdict: Incorrect**\n\nIn summary, the histopathological findings, particularly the morphology of the collagen and the paucity of myofibroblasts, are classic for a keloid. Option A is the only choice that makes the correct diagnosis and provides an accurate and consistent explanation based on the provided data.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Intralesional corticosteroid injection is a cornerstone of keloid treatment, but its success hinges on precise delivery. This exercise moves beyond simply memorizing a drug concentration and prompts you to think like a practitioner by calculating the exact volume and injection grid spacing needed to achieve a target dose density safely. Mastering this quantitative approach is essential for optimizing therapeutic outcomes while minimizing local side effects such as atrophy .",
            "id": "4630545",
            "problem": "A patient presents with a keloid requiring intralesional corticosteroid therapy. You plan to use Triamcinolone Acetonide (TA) at a concentration of $40$ $\\text{mg}/\\text{mL}$ to achieve a target dose density of $0.8$ $\\text{mg}/\\text{cm}^{2}$ uniformly across a lesion area of $5$ $\\text{cm}^{2}$. In planning injections for a square grid pattern, you will deposit equal volume at each grid intersection. To reduce the risk of dermal atrophy and telangiectasia, assume a commonly used upper limit of $V_{\\text{max}} = 0.1$ $\\text{mL}$ per depot (single injection at one point).\n\nStarting only from the core definitions that:\n- concentration $C$ is mass per volume, $C = \\frac{M}{V}$,\n- dose density $\\delta$ is mass per area, $\\delta = \\frac{M}{A}$,\n\nand basic geometric partitioning of area by a square grid of spacing $s$ (so that the area served per depot is $s^{2}$), derive the expressions needed to determine:\n1. the total injection volume $V_{\\text{total}}$ (in $\\text{mL}$) required to achieve the target dose density over the lesion area, and\n2. the maximum safe grid spacing $s$ (in $\\text{cm}$) that ensures the per-depot volume does not exceed $V_{\\text{max}}$.\n\nThen compute the numerical values using $C = 40$ $\\text{mg}/\\text{mL}$, $\\delta = 0.8$ $\\text{mg}/\\text{cm}^{2}$, $A = 5$ $\\text{cm}^{2}$, and $V_{\\text{max}} = 0.1$ $\\text{mL}$. Provide your final answer as a row matrix $\\begin{pmatrix}V_{\\text{total}} & s\\end{pmatrix}$, where $V_{\\text{total}}$ is expressed in $\\text{mL}$ and $s$ in $\\text{cm}$. Round both values to three significant figures.",
            "solution": "The problem will be validated before a solution is attempted.\n\n### Step 1: Extract Givens\nThe data, variables, definitions, and conditions explicitly given in the problem statement are:\n- Concentration of Triamcinolone Acetonide (TA): $C = 40 \\text{ mg}/\\text{mL}$\n- Target dose density: $\\delta = 0.8 \\text{ mg}/\\text{cm}^{2}$\n- Lesion area: $A = 5 \\text{ cm}^{2}$\n- Maximum volume per depot: $V_{\\text{max}} = 0.1 \\text{ mL}$\n- Definition of concentration: $C = \\frac{M}{V}$\n- Definition of dose density: $\\delta = \\frac{M}{A}$\n- Model assumption: square grid pattern of spacing $s$, where the area served per depot is $s^{2}$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed against the validation criteria:\n- **Scientifically Grounded**: The problem is set in a realistic clinical context (intralesional corticosteroid injection for keloids), using standard medications (Triamcinolone Acetonide), concentrations, and therapeutic concepts (dose density). The definitions of concentration and dose density are fundamental and correct. The values provided are within clinically accepted ranges.\n- **Well-Posed**: The problem asks for the derivation and calculation of two specific quantities, $V_{\\text{total}}$ and $s$. All necessary definitions, variables, and constraints are provided to determine a unique and meaningful solution.\n- **Objective**: The problem is stated using precise, quantitative, and unbiased language. There are no subjective or ambiguous terms.\n- **Completeness and Consistency**: The problem is self-contained. The provided data are dimensionally consistent and do not contain contradictions. For example, the units of $C$, $\\delta$, $A$, and $V_{\\text{max}}$ are compatible for the required calculations.\n- **Feasibility**: The physical scenario and the required calculations are realistic and feasible.\n\nThe problem does not violate any of the invalidity criteria. It is scientifically sound, well-posed, objective, complete, and feasible.\n\n### Step 3: Verdict and Action\nThe problem is valid. A complete solution will be provided.\n\n### Solution Derivation\n\nThe derivation proceeds in two parts as requested: first for the total injection volume $V_{\\text{total}}$, and second for the maximum safe grid spacing $s$.\n\n**1. Derivation and Calculation of Total Injection Volume ($V_{\\text{total}}$)**\n\nThe total mass of Triamcinolone Acetonide, $M_{\\text{total}}$, required to cover the entire lesion area $A$ at the target dose density $\\delta$ is determined by the definition of dose density:\n$$\n\\delta = \\frac{M_{\\text{total}}}{A}\n$$\nSolving for $M_{\\text{total}}$ yields:\n$$\nM_{\\text{total}} = \\delta A\n$$\nThe total volume of the solution, $V_{\\text{total}}$, required to deliver this total mass $M_{\\text{total}}$ is determined by the concentration $C$ of the solution:\n$$\nC = \\frac{M_{\\text{total}}}{V_{\\text{total}}}\n$$\nSolving for $V_{\\text{total}}$ and substituting the expression for $M_{\\text{total}}$ gives the general formula:\n$$\nV_{\\text{total}} = \\frac{M_{\\text{total}}}{C} = \\frac{\\delta A}{C}\n$$\nNow, we substitute the given numerical values: $C = 40 \\text{ mg}/\\text{mL}$, $\\delta = 0.8 \\text{ mg}/\\text{cm}^{2}$, and $A = 5 \\text{ cm}^{2}$.\n$$\nV_{\\text{total}} = \\frac{(0.8 \\text{ mg}/\\text{cm}^{2}) \\times (5 \\text{ cm}^{2})}{40 \\text{ mg}/\\text{mL}} = \\frac{4 \\text{ mg}}{40 \\text{ mg}/\\text{mL}} = 0.1 \\text{ mL}\n$$\nRounding to three significant figures, $V_{\\text{total}} = 0.100 \\text{ mL}$.\n\n**2. Derivation and Calculation of Maximum Safe Grid Spacing ($s$)**\n\nThe problem models the injection pattern as a square grid of spacing $s$. It assumes that each injection depot, located at a grid intersection, serves a square area of $A_{\\text{depot}} = s^{2}$.\n\nTo maintain a uniform dose density $\\delta$, the mass delivered at each depot, $M_{\\text{depot}}$, must be proportional to the area it serves:\n$$\n\\delta = \\frac{M_{\\text{depot}}}{A_{\\text{depot}}} = \\frac{M_{\\text{depot}}}{s^{2}}\n$$\nSolving for the mass per depot:\n$$\nM_{\\text{depot}} = \\delta s^{2}\n$$\nThe volume injected at each depot, $V_{\\text{depot}}$, is determined by the concentration $C$:\n$$\nC = \\frac{M_{\\text{depot}}}{V_{\\text{depot}}}\n$$\nSolving for $V_{\\text{depot}}$ and substituting the expression for $M_{\\text{depot}}$:\n$$\nV_{\\text{depot}} = \\frac{M_{\\text{depot}}}{C} = \\frac{\\delta s^{2}}{C}\n$$\nThe problem states a safety constraint that the volume per depot must not exceed $V_{\\text{max}}$:\n$$\nV_{\\text{depot}} \\le V_{\\text{max}}\n$$\nSubstituting our expression for $V_{\\text{depot}}$:\n$$\n\\frac{\\delta s^{2}}{C} \\le V_{\\text{max}}\n$$\nThe maximum safe grid spacing, $s$, corresponds to the equality, where the volume per depot is exactly at its upper limit:\n$$\n\\frac{\\delta s^{2}}{C} = V_{\\text{max}}\n$$\nWe now solve for $s$:\n$$\ns^{2} = \\frac{V_{\\text{max}} C}{\\delta}\n$$\n$$\ns = \\sqrt{\\frac{V_{\\text{max}} C}{\\delta}}\n$$\nNow, we substitute the given numerical values: $V_{\\text{max}} = 0.1 \\text{ mL}$, $C = 40 \\text{ mg}/\\text{mL}$, and $\\delta = 0.8 \\text{ mg}/\\text{cm}^{2}$.\n$$\ns = \\sqrt{\\frac{(0.1 \\text{ mL}) \\times (40 \\text{ mg}/\\text{mL})}{0.8 \\text{ mg}/\\text{cm}^{2}}} = \\sqrt{\\frac{4 \\text{ mg}}{0.8 \\text{ mg}/\\text{cm}^{2}}} = \\sqrt{5 \\text{ cm}^{2}} = \\sqrt{5} \\text{ cm}\n$$\nCalculating the numerical value of $\\sqrt{5}$:\n$$\ns \\approx 2.2360679... \\text{ cm}\n$$\nRounding to three significant figures, $s = 2.24 \\text{ cm}$.\n\nThe final requested values are $V_{\\text{total}} = 0.100 \\text{ mL}$ and $s = 2.24 \\text{ cm}$.",
            "answer": "$$\n\\boxed{\\begin{pmatrix} 0.100 & 2.24 \\end{pmatrix}}\n$$"
        },
        {
            "introduction": "When scar contractures impair function, surgical revision becomes necessary, and the Z-plasty is a fundamental tool in the surgeon's armamentarium. This practice delves into the elegant geometry that underpins this powerful technique, tasking you with deriving the principles of tissue lengthening from first principles. By connecting a surgical design parameter, the flap angle $\\theta$, to a functional outcome, you will gain a deeper appreciation for the mathematical precision required in reconstructive surgery .",
            "id": "4630631",
            "problem": "A patient presents with a linear hypertrophic scar spanning a flexion crease on the volar forearm that is oriented perpendicular to the Relaxed Skin Tension Lines (RSTL). The scar produces a measurable contracture. You plan a single Z-plasty with equal limbs to redistribute tension by reorienting the central limb closer to the RSTL and to lengthen the contracted segment. Assume the following scientifically realistic and standard geometric design constraints for a Z-plasty in planar soft tissue: the two lateral limbs have equal length to the central limb, each lateral limb is incised at the same angle $\\theta$ to the central limb, and transposition is ideal (negligible tissue loss and perfect flap viability), so that flap edges meet without mismatch.\n\nStarting only from core geometric definitions in the plane and the transposition properties of Z-plasty (two congruent triangular flaps exchanging positions across the central limb), derive the analytic expression for the increase in the central limb length as a function of the original central limb length $s$ and the design angle $\\theta$. Then, for a $60^{\\circ}$ design with an original central limb length of $s = 7.5\\,\\text{cm}$ on a forearm segment of functional length $L = 34\\,\\text{cm}$ (measured between fixed bony landmarks spanning the contracted arc), compute the expected lengthening as a decimal fraction of the limb length, that is, compute $\\Delta/L$ where $\\Delta$ is the increase in central limb length produced by the Z-plasty.\n\nExpress the final result as a decimal fraction without a percentage sign. Round your answer to four significant figures.",
            "solution": "The user wants me to solve a problem that involves deriving an analytical expression and then performing a numerical calculation, both of which pertain to the surgical procedure known as Z-plasty.\n\n### Step 1: Problem Validation\n\nFirst, I will validate the problem statement according to the specified criteria.\n\n#### Step 1.1: Extract Givens\n- **Procedure**: Single Z-plasty for a linear hypertrophic scar contracture.\n- **Location**: Volar forearm, spanning a flexion crease.\n- **Orientation**: Scar is perpendicular to Relaxed Skin Tension Lines (RSTL).\n- **Goal**: Redistribute tension and lengthen the contracted segment.\n- **Geometric Constraints**:\n    - Central limb length is $s$.\n    - Two lateral limbs have length equal to the central limb, i.e., $s$.\n    - Each lateral limb is incised at the same angle $\\theta$ to the central limb.\n- **Assumptions**: Ideal transposition (negligible tissue loss, perfect flap viability, no edge mismatch).\n- **Task 1 (Derivation)**: Derive the analytic expression for the increase in the central limb length, $\\Delta$, as a function of $s$ and $\\theta$.\n- **Task 2 (Calculation)**:\n    - For a specific design: $\\theta = 60^{\\circ}$, original central limb length $s = 7.5\\,\\text{cm}$, functional forearm segment length $L = 34\\,\\text{cm}$.\n    - Compute the expected lengthening as a decimal fraction of the functional length: $\\Delta/L$.\n    - Round the final result to four significant figures.\n\n#### Step 1.2: Validate Using Extracted Givens\n- **Scientific Grounding**: The problem describes a Z-plasty, a standard and fundamental procedure in plastic and reconstructive surgery. The geometric analysis of lengthening is a core part of its theory and application. The concepts of RSTL and scar contracture are central to the clinical context. The specified parameters ($\\theta=60^{\\circ}$, $s=7.5\\,\\text{cm}$, $L=34\\,\\text{cm}$) are clinically realistic. The problem is scientifically sound.\n- **Well-Posed**: The problem is well-defined. It asks for a specific derivation and a specific calculation. The geometric constraints are clear, allowing for a unique mathematical model to be constructed and solved.\n- **Objective**: The language is technical, precise, and free of subjectivity or bias.\n- **Flaw Check**:\n    1.  **Scientific Unsoundness**: None. The problem is based on established principles of geometry and surgery.\n    2.  **Non-Formalizable/Irrelevant**: None. The problem is a direct application of geometry to a surgical procedure, relevant to *general surgery* and its subspecialties.\n    3.  **Incomplete/Contradictory**: None. All necessary variables ($s$, $\\theta$, $L$) and constraints are provided.\n    4.  **Unrealistic/Infeasible**: None. The physical situation and values are plausible.\n    5.  **Ill-Posed**: None. A unique, stable solution is attainable.\n    6.  **Trivial/Tautological**: None. The derivation requires non-trivial geometric reasoning.\n    7.  **Outside Verifiability**: None. The derivation is subject to standard mathematical verification.\n\n#### Step 1.3: Verdict and Action\nThe problem is **valid**. I will proceed with the solution.\n\n### Step 2: Solution\n\nThe problem requires a two-part solution: first, the derivation of a general formula for the increase in length, and second, a numerical calculation for a specific case.\n\n#### Part 1: Derivation of the Lengthening Formula\n\nWe model the Z-plasty incisions in a 2D Cartesian coordinate system. Let the original central limb, which corresponds to the scar contracture, be represented by a line segment of length $s$. For simplicity, we place its endpoints at $A$ and $B$. Let $A$ be at the origin $(0,0)$ and $B$ be at $(s,0)$. The original length of the contracture is the distance between $A$ and $B$, which is $s$.\n\nThe Z-plasty consists of two lateral limbs of length $s$, one at each end of the central limb. Let these be $AC$ and $BD$. The problem states that each lateral limb is incised at an angle $\\theta$ to the central limb, and the flaps are on opposite sides.\n\n- The limb $AC$ starts at $A(0,0)$ and has length $s$. The angle between the vector $\\vec{AC}$ and the vector $\\vec{AB}$ is $\\theta$. We can place point $C$ in the upper half-plane. Its coordinates are $C = (s\\cos\\theta, s\\sin\\theta)$.\n\n- The limb $BD$ starts at $B(s,0)$ and has length $s$. The angle between the vector $\\vec{BD}$ and the vector $\\vec{BA}$ (which points along the negative x-axis) is $\\theta$. Therefore, the vector $\\vec{BD}$ makes an angle of $\\pi + \\theta$ with the positive x-axis. To place $D$ on the opposite side of the central limb from $C$, we use an angle of $-\\theta$ relative to the vector $\\vec{BA}$ or $\\pi - \\theta$ relative to $\\vec{BA}$. A more direct approach is to make the angle between $\\vec{BD}$ and $\\vec{AB}_{ext}$ (positive x-axis) equal to $-\\theta$. However, the standard convention of Z-plasty geometry places the angle $\\theta$ as the internal angle between the central limb and the lateral limb. This implies vector $\\vec{BA}$ rotated by $\\theta$ to get $\\vec{BD}$. The angle of $\\vec{BA}$ is $\\pi$. Thus the angle of $\\vec{BD}$ is $\\pi+\\theta$ or $\\pi-\\theta$. Let's place D in the lower half-plane. A vector starting at B with angle $\\pi+\\theta$ relative to the positive x-axis has components $(s\\cos(\\pi+\\theta), s\\sin(\\pi+\\theta)) = (-s\\cos\\theta, -s\\sin\\theta)$. The coordinates of $D$ would be $D = B + (-s\\cos\\theta, -s\\sin\\theta) = (s-s\\cos\\theta, -s\\sin\\theta)$.\n\nSo, our points are:\n$A = (0, 0)$\n$B = (s, 0)$\n$C = (s\\cos\\theta, s\\sin\\theta)$\n$D = (s-s\\cos\\theta, -s\\sin\\theta)$\n\nDuring the Z-plasty transposition, the two triangular flaps are repositioned. The geometric result of this maneuver is that the points $A$ and $B$, which define the original line of contracture, are pulled apart. The new central limb of the reconstructed tissue lies along the line connecting the original tips of the lateral flaps, $C$ and $D$. The new length, $s'$, is the distance between $C$ and $D$.\n\nWe calculate the square of the distance $|CD|$:\n$$s'^2 = |CD|^2 = (x_D - x_C)^2 + (y_D - y_C)^2$$\nThe differences in coordinates are:\n$$x_D - x_C = (s - s\\cos\\theta) - s\\cos\\theta = s - 2s\\cos\\theta = s(1 - 2\\cos\\theta)$$\n$$y_D - y_C = -s\\sin\\theta - s\\sin\\theta = -2s\\sin\\theta$$\nSubstituting these into the distance formula:\n$$s'^2 = [s(1 - 2\\cos\\theta)]^2 + (-2s\\sin\\theta)^2$$\n$$s'^2 = s^2(1 - 4\\cos\\theta + 4\\cos^2\\theta) + 4s^2\\sin^2\\theta$$\n$$s'^2 = s^2 - 4s^2\\cos\\theta + 4s^2\\cos^2\\theta + 4s^2\\sin^2\\theta$$\nUsing the trigonometric identity $\\cos^2\\theta + \\sin^2\\theta = 1$:\n$$s'^2 = s^2 - 4s^2\\cos\\theta + 4s^2(\\cos^2\\theta + \\sin^2\\theta)$$\n$$s'^2 = s^2 - 4s^2\\cos\\theta + 4s^2 = 5s^2 - 4s^2\\cos\\theta$$\n$$s'^2 = s^2(5 - 4\\cos\\theta)$$\nThe new length $s'$ is the square root of this expression:\n$$s' = s\\sqrt{5 - 4\\cos\\theta}$$\nThe increase in length, $\\Delta$, is the difference between the new length and the original length $s$:\n$$\\Delta = s' - s = s\\sqrt{5 - 4\\cos\\theta} - s$$\nFactoring out $s$, we arrive at the analytic expression for the increase in length:\n$$\\Delta = s(\\sqrt{5 - 4\\cos\\theta} - 1)$$\n\n#### Part 2: Numerical Calculation\n\nWe are given the following values for a specific surgical plan:\n- Design angle: $\\theta = 60^{\\circ}$\n- Original central limb length: $s = 7.5\\,\\text{cm}$\n- Functional forearm segment length: $L = 34\\,\\text{cm}$\n\nWe need to compute $\\Delta/L$. First, we calculate $\\Delta$ using the derived formula with $\\theta = 60^{\\circ}$. The cosine of this angle is:\n$$\\cos(60^{\\circ}) = \\frac{1}{2}$$\nSubstitute this value into the expression for $\\Delta$:\n$$\\Delta = s\\left(\\sqrt{5 - 4\\left(\\frac{1}{2}\\right)} - 1\\right)$$\n$$\\Delta = s(\\sqrt{5 - 2} - 1)$$\n$$\\Delta = s(\\sqrt{3} - 1)$$\nNow, we substitute the given value $s = 7.5\\,\\text{cm}$:\n$$\\Delta = 7.5(\\sqrt{3} - 1)\\,\\text{cm}$$\nThe problem asks for the quantity $\\Delta/L$, where $L = 34\\,\\text{cm}$. This represents the lengthening as a fraction of the total functional length of the limb segment.\n$$\\frac{\\Delta}{L} = \\frac{7.5(\\sqrt{3} - 1)}{34}$$\nTo obtain the numerical value, we use the approximation $\\sqrt{3} \\approx 1.73205$:\n$$\\frac{\\Delta}{L} \\approx \\frac{7.5(1.73205 - 1)}{34} = \\frac{7.5(0.73205)}{34}$$\n$$\\frac{\\Delta}{L} \\approx \\frac{5.490375}{34} \\approx 0.1614816$$\nThe problem requires the answer to be rounded to four significant figures.\n$$0.1614816 \\approx 0.1615$$\nThe expected lengthening is $0.1615$ of the functional limb length.",
            "answer": "$$\\boxed{0.1615}$$"
        }
    ]
}